Hermetica Superfood Encyclopedia
The Short Answer
3-Epi-25-Hydroxyvitamin D3 (3-epi-25(OH)D3) is a C-3 epimer of 25-hydroxyvitamin D3 generated during hepatic vitamin D3 metabolism, differing only in the α-stereochemistry of its C-3 hydroxyl group, and circulates in adult serum at a weighted mean of approximately 1.72 ng/mL (4.3 nmol/L), representing roughly 6.1% of total 25(OH)D3. Animal data show that dietary 3-epi-25(OH)D3 at 0.5–1 IU/g suppresses serum parathyroid hormone (PTH) in male weanling rats, and supplementation with 20 µg/day vitamin D3 in adult humans raises circulating 3-epi-25(OH)D3 concentrations by 42.1% over 15 weeks, though no confirmed therapeutic benefit in humans has been established.
CategoryCompound
GroupMineral
Evidence LevelPreliminary
Primary Keyword3-epi-25-hydroxyvitamin D3
3-Epi-25-Hydroxyvitamin D3 — botanical close-up
Health Benefits
**Parathyroid Hormone Modulation (Preclinical)**
Animal studies in male weanling rats demonstrate that dietary 3-epi-25(OH)D3 at doses of 0.5–1 IU/g significantly lowers serum PTH, suggesting a potential role in calcium-phosphate homeostasis analogous to but distinct from 25(OH)D3; this effect was not observed in female rats, indicating sex-dependent biological activity.
**Vitamin D Status Biomarker**
3-epi-25(OH)D3 circulates at detectable concentrations in up to 96.4% of adult populations and rises proportionally with vitamin D3 supplementation (42.1% increase with 20 µg/day over 15 weeks), making it a quantifiable indicator of vitamin D3 metabolic activity in serum.
**Potential Contribution to Total Vitamin D Activity**
Because immunoassay-based 25(OH)D3 measurements cross-react with 3-epi-25(OH)D3, the epimer may contribute to apparent total vitamin D bioactivity as measured clinically, though its intrinsic potency at the vitamin D receptor (VDR) relative to 25(OH)D3 has not been rigorously quantified in humans.
**Differential Pediatric Physiology Marker**
Infants exhibit disproportionately higher proportional concentrations of 3-epi-25(OH)D3 relative to adults, with a progressive age-related decline, suggesting the epimer may reflect distinct metabolic processing of vitamin D3 in developing physiology and could serve as a developmental biomarker.
**Renal and Inflammatory Disease Indicator**
Observational data link elevated C3-epi-25(OH)D3 proportions to chronic kidney disease severity in patients with rheumatoid arthritis, implying the epimer may accumulate when normal vitamin D metabolic pathways are disrupted and could signal impaired renal 1α-hydroxylation capacity.
**Assay Calibration and Diagnostic Accuracy**
Recognition of 3-epi-25(OH)D3 as a distinct circulating species is clinically important because its cross-reactivity with conventional immunoassays can overestimate bioavailable 25(OH)D3 by up to several nmol/L, particularly in infants and supplemented individuals, necessitating LC-MS/MS-based discrimination for accurate vitamin D status classification.
Origin & History
Natural habitat
3-Epi-25-Hydroxyvitamin D3 is an endogenous metabolite produced in the human liver during the metabolism of vitamin D3 (cholecalciferol), which originates from either cutaneous synthesis upon ultraviolet-B irradiation of 7-dehydrocholesterol or from dietary intake of vitamin D3-containing foods and supplements. It is not derived from any botanical source or geographic region, but rather arises as a minor epimeric byproduct of hepatic 25-hydroxylation of vitamin D3, differing from the parent metabolite 25-hydroxyvitamin D3 (25(OH)D3) solely in the stereochemical orientation of the hydroxyl group at carbon position C-3 (α-orientation versus the β-orientation in 25(OH)D3). Concentrations are detectable in virtually all human populations studied, with notably higher proportional levels in infants that decline progressively with age, and levels are influenced by geographic latitude, sunlight exposure, and oral vitamin D3 supplementation.
“3-Epi-25-Hydroxyvitamin D3 has no history of use in any traditional medicine system, herbal practice, or cultural healing tradition, as it was unknown prior to the development of high-resolution liquid chromatography–tandem mass spectrometry (LC-MS/MS) techniques in the late 20th and early 21st centuries. Its identification as a distinct circulating vitamin D metabolite in human serum emerged from efforts to improve the analytical specificity of vitamin D status testing, with foundational characterization work published in the 2000s and 2010s as researchers recognized that conventional immunoassays could not discriminate between 25(OH)D3 and its C-3 epimer. The compound's biological and clinical relevance was brought to prominence by observations that infants, who had been thought to have unexpectedly high vitamin D levels by immunoassay, in fact had large proportions of 3-epi-25(OH)D3 cross-reacting with antibody-based tests, prompting reassessment of pediatric vitamin D reference ranges. It remains strictly a subject of modern analytical chemistry and clinical laboratory science, with no traditional preparation, ethnobotanical record, or cultural medicinal significance.”Traditional Medicine
Scientific Research
The clinical evidence base for 3-epi-25(OH)D3 is confined almost entirely to pharmacokinetic and observational studies focused on its measurement as a biomarker rather than its therapeutic efficacy, representing a very early and limited evidence tier. One randomized controlled trial (NCT01990872) in adults aged ≥50 years receiving 20 µg/day vitamin D3 for 15 weeks documented a statistically significant 42.1% increase in serum 3-epi-25(OH)D3 (P<0.0001) versus a -29.1% reduction in the placebo arm, establishing pharmacodynamic responsiveness but not therapeutic endpoints. A large cross-sectional study of 1,082 Irish adults quantified 3-epi-25(OH)D3 in 96.4% of participants (mean 2.50 nmol/L, median 2.18 nmol/L) using LC-MS/MS, while U.S. NHANES-derived analyses found it quantifiable in 33.4% of white and 15.0% of Black adults at a weighted mean of 1.72 ng/mL, highlighting population-level variability. Preclinical data from male weanling rat models provide the sole evidence of biological activity beyond biomarker status, and no human efficacy trials, meta-analyses, or systematic reviews examining 3-epi-25(OH)D3 as an intervention exist, placing overall evidence quality at the preliminary-to-preclinical level.
Preparation & Dosage
Traditional preparation
**Research-Grade Analytical Standard (Powder)**
Available at ≥98% purity from specialty chemical suppliers (e.g., Sigma-Aldrich, Cayman Chemical) for use as a reference standard in LC-MS/MS vitamin D metabolite assays; stored at -20°C under inert atmosphere; not formulated for human consumption.
**Deuterated Isotope-Labeled Form**
Deuterium-labeled variants (e.g., 3-epi-25(OH)D3-d6) are available as internal standards for quantitative mass spectrometry; these are analytical reagents only and carry no dosage context for supplementation.
**Endogenous Formation via Vitamin D3 Supplementation**
800 IU/day) for 15 weeks raised serum levels by 42
The only practical means by which circulating 3-epi-25(OH)D3 is increased in humans is through oral vitamin D3 (cholecalciferol) supplementation; a dose of 20 µg/day (.1% in one RCT, though this was an incidental finding rather than a therapeutic target.
**No Established Human Supplement Form**
There is no approved, commercially available, or clinically validated supplement formulation of 3-epi-25(OH)D3; no effective dose range, bioavailability data, or standardization specification exists for human use.
**Preclinical Oral Dosing (Animal Only)**
5–1 IU/g feed to observe PTH suppression; these doses have no validated human equivalent and should not be extrapolated for clinical application
Male weanling rat studies used dietary concentrations of 0..
Nutritional Profile
3-Epi-25-Hydroxyvitamin D3 is a steroidal secosteroid metabolite with a molecular formula of C27H44O2 and a molecular weight of approximately 400.64 g/mol, sharing this formula with its parent compound 25-hydroxyvitamin D3 (calcifediol). It is not a macronutrient, micronutrient in the dietary sense, or phytochemical; it is a minor endogenous metabolite present in human serum at concentrations typically ranging from 0 to 117 nmol/L (with most adults in the 1–5 nmol/L range) and represents approximately 2–6% of total circulating 25(OH)D3 under normal conditions. It is not present in measurable quantities in foods, not synthesized in the skin, and not available in any nutritional matrix; its circulating level is entirely a function of hepatic epimerization of vitamin D3-derived 25(OH)D3. Bioavailability in the dietary sense is not applicable; absorption and distribution characteristics have not been studied independently from the parent vitamin D3 metabolic cascade.
How It Works
Mechanism of Action
3-Epi-25-Hydroxyvitamin D3 arises from epimerization of the C-3 hydroxyl group of 25-hydroxyvitamin D3 from the native β-configuration to the α-configuration, a reaction believed to occur in the liver as a minor shunt pathway of vitamin D3 metabolism, though the specific enzyme(s) responsible for this epimerization have not been conclusively identified. At the molecular level, the epimer's altered C-3 stereochemistry is hypothesized to reduce its affinity for vitamin D-binding protein (DBP) and potentially alter its interaction with the nuclear vitamin D receptor (VDR), but direct ligand-binding and transactivation studies in human cell lines are lacking, and no downstream changes in CYP24A1, TRPV6, or other VDR target gene expression attributable specifically to 3-epi-25(OH)D3 have been reported in human studies. In male weanling rats, the compound suppresses PTH secretion from the parathyroid gland, suggesting at minimum partial agonism at calcium-sensing or VDR-mediated pathways governing PTH gene transcription, though the receptor responsible and the effect size relative to equimolar 25(OH)D3 remain uncharacterized. Rising serum concentrations following oral vitamin D3 supplementation confirm that endogenous production scales with substrate availability, indicating the epimerization pathway is not saturable at typical supplemental doses of 20 µg/day.
Clinical Evidence
No clinical trials have evaluated 3-epi-25(OH)D3 as a standalone therapeutic intervention; all human trial data pertain to its measurement as a secondary outcome within vitamin D3 supplementation studies. The most informative trial (NCT01990872, adults ≥50 years, 20 µg/day vitamin D3, 15 weeks) demonstrated that the epimer's serum concentration rises significantly and proportionally with vitamin D3 dosing, confirming endogenous metabolic formation rather than independent pharmacological action. Observational studies suggest that high proportional 3-epi-25(OH)D3 relative to total 25(OH)D3 may correlate with impaired vitamin D metabolism in disease states such as chronic kidney disease and rheumatoid arthritis, where the ratio may serve as a diagnostic confounder in immunoassay-based vitamin D testing. Confidence in any therapeutic role is extremely low given the complete absence of efficacy endpoints, dose-response clinical data, or safety trials for supplemental administration in humans.
Safety & Interactions
No human safety data exist for supplemental or therapeutic administration of 3-epi-25(OH)D3, as it has never been developed as a clinical or nutritional product; all safety inferences are derived from its chemical classification and analytical-grade material safety data sheets. Commercial research-grade powder carries hazard classifications including acute oral, dermal, and inhalation toxicity (H301+H311, H330) and specific target organ toxicity via repeated oral exposure (H372), consistent with the known toxicological profile of vitamin D metabolite analogs at high doses, though these designations reflect laboratory handling scenarios rather than physiological supplementation. No drug interactions, contraindications, or reproductive safety data have been reported, as the compound has not entered clinical pharmacology studies; however, given that it shares structural similarity with 25(OH)D3 and may partially engage VDR or DBP pathways, theoretical risks of vitamin D toxicity syndrome (hypercalcemia, hypercalciuria, nephrocalcinosis) at supraphysiological doses cannot be excluded. Until human pharmacokinetic, dose-escalation, and safety studies are conducted, no safe supplemental dose can be defined, and use outside of controlled research settings is not supported by any regulatory body.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
3-epi-25(OH)D33α-hydroxy-vitamin D3 25-hydroxylateC-3 epimer of calcifediol3-epi-calcifediol3-epi-25-hydroxycholecalciferol
Frequently Asked Questions
What is 3-epi-25-hydroxyvitamin D3 and how is it different from regular vitamin D?
3-Epi-25-hydroxyvitamin D3 is a minor metabolite of vitamin D3 formed in the liver that differs from the standard metabolite 25-hydroxyvitamin D3 (calcifediol) only in the stereochemical orientation of the hydroxyl group at carbon position C-3, where it adopts an α-configuration instead of the normal β-configuration. This structural difference is subtle but measurable by LC-MS/MS, and the epimer circulates in adult serum at concentrations averaging approximately 1.72 ng/mL (about 6.1% of total 25(OH)D3), though its biological potency at the vitamin D receptor relative to 25(OH)D3 has not been definitively established in humans.
Does 3-epi-25-hydroxyvitamin D3 affect vitamin D blood test results?
Yes, 3-epi-25-hydroxyvitamin D3 cross-reacts with antibody-based immunoassay platforms commonly used to measure 25(OH)D3 in clinical laboratories, which can lead to overestimation of true 25(OH)D3 concentrations, particularly in infants and individuals taking high-dose vitamin D3 supplements. This is clinically significant in pediatric populations, where the proportion of 3-epi-25(OH)D3 relative to total circulating 25(OH)D3 can be substantially higher than in adults; LC-MS/MS-based testing, which can distinguish between the two compounds, is recommended when precise vitamin D status classification is required.
Is 3-epi-25-hydroxyvitamin D3 available as a supplement?
No, 3-epi-25-hydroxyvitamin D3 is not available as a nutritional or pharmaceutical supplement for human use; it exists commercially only as a high-purity (≥98%) analytical reference standard and deuterium-labeled internal standard intended for laboratory mass spectrometry assays. No regulatory agency has approved it as a dietary ingredient, no clinical dose has been established, and its safety profile in humans following supplemental administration has never been studied.
Why do infants have higher levels of 3-epi-25-hydroxyvitamin D3 than adults?
Infants consistently show higher proportional concentrations of 3-epi-25(OH)D3 relative to total circulating 25(OH)D3 compared to adults, a pattern that declines progressively with age, though the precise enzymatic or developmental mechanisms responsible for this difference have not been fully characterized. This age-related variation is clinically important because it means that vitamin D status assessed by immunoassay in infants is more susceptible to overestimation from epimer cross-reactivity than in adults, and some infants previously classified as vitamin D sufficient by immunoassay may have had a significant portion of their measured 25(OH)D3 attributable to the biologically distinct epimer.
What does research say about the health effects of 3-epi-25-hydroxyvitamin D3?
Human research on 3-epi-25(OH)D3 is limited to pharmacokinetic observations and its role as a diagnostic biomarker; the most notable human finding is that serum levels rise by 42.1% (P<0.0001) following 15 weeks of 20 µg/day vitamin D3 supplementation in adults over 50, confirming it is an endogenous metabolite whose formation scales with vitamin D3 availability. The only evidence of independent biological activity comes from animal studies in male weanling rats, in which dietary 3-epi-25(OH)D3 at 0.5–1 IU/g suppressed serum PTH, but this preclinical finding has not been translated into human trials, and no therapeutic application has been established.
Does 3-epi-25-hydroxyvitamin D3 have sex-specific effects on calcium and phosphate balance?
Yes, research in male weanling rats shows that 3-epi-25(OH)D3 significantly lowers serum parathyroid hormone (PTH) levels at doses of 0.5–1 IU/g, suggesting a role in calcium-phosphate homeostasis. However, this PTH-lowering effect was not observed in female rats, indicating that the biological activity of 3-epi-25(OH)D3 is sex-dependent. This sex-specific response distinguishes it from standard vitamin D3 and suggests potential differences in how males and females metabolize or respond to this compound.
Is 3-epi-25-hydroxyvitamin D3 an active form of vitamin D like calcitriol?
3-epi-25(OH)D3 is not the most active form of vitamin D; calcitriol (1,25-dihydroxyvitamin D3) holds that distinction. However, 3-epi-25(OH)D3 does demonstrate biological activity distinct from its parent compound 25(OH)D3, as evidenced by its sex-specific effects on PTH regulation in animal models. The exact mechanisms and potency of 3-epi-25(OH)D3 compared to other vitamin D metabolites remain an active area of research.
Who might have naturally elevated 3-epi-25-hydroxyvitamin D3 levels besides infants?
While infants are known to have higher baseline levels of 3-epi-25(OH)D3 than adults, individuals with certain kidney or metabolic disorders that affect vitamin D metabolism may also exhibit elevated levels. Pregnant women and those with specific genetic polymorphisms in vitamin D metabolizing enzymes may show variations in 3-epi-25(OH)D3 production, though more clinical research is needed to fully characterize these populations. Monitoring this metabolite may be particularly relevant for groups with altered vitamin D metabolism.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w 3-epi-25-hydroxyvitamin-d3 curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
